CARMEL, Ind., Jan. 16, 2024 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA) ("Syra Health" or the "Company"), a healthcare technology company with a mission to improve healthcare by providing innovative services and technology solutions, announced today that it will be participating in Lytham Partners 2024 Investor Select Conference taking place virtually on February 1, 2024.
1x1 Meetings
Syra Health Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1x1@lythampartners.com or register at https://lythampartners.com/select2024invreg/.
Further information on the conference is available at https://lythampartners.com/select2024.
ABOUT SYRA HEALTH CORP.
Syra Health is a healthcare technology company addressing some of healthcare's most significant challenges in areas such as behavioral and mental health, digital health, and population health, by providing innovative services and technology solutions. Syra Health's products and services are centered on prevention, improved access, and affordable care. Syra Health supplies its solutions to payers, providers, life sciences organizations, academic institutions, and the government. For more information, please visit www.syrahealth.com.
For more information, please contact:
For Media Inquiries:
Christine Drury
Communications and Marketing Director
Syra Health Corp.
463-345-5180
For Investor Inquiries:
Ben Shamsian
Vice President
Lytham Partners, LLC
646-829-9701
| Last Trade: | US$0.08 |
| Daily Change: | -0.02 -23.30 |
| Daily Volume: | 3,261 |
| Market Cap: | US$718K |
February 18, 2025 December 02, 2024 November 26, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
